New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:15 EDTFCEL, VIPS, FTEK, MYGN, LJPC, BONT, ZBB, AEO, JCP, BYD, PLUG, EJOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FuelCell (FCEL), up 16%. Shares of alternative energy industry peers Plug Power (PLUG), up 9%, and ZBB Energy (ZBB), up 16%, are also higher in pre-market trading. ALSO HIGHER: Boyd Gaming (BYD), up 14% after activist investor Elliott disclosed a stake in the company that includes a 4.99% voting interest and a total economic exposure of 7%... La Jolla Pharmaceutical (LJPC), up 71% after announcing that its Phase 2 trial of GCS-100 in chronic kidney disease reached its primary and key secondary endpoints... J.C. Penney (JCP), up 7.5% following upgrade to Buy rating at Citigroup. DOWN AFTER EARNINGS: American Eagle (AEO), down 5%... Bon-Ton Stores (BONT), down 5.7%... Fuel Tech (FTEK), down 20%. ALSO LOWER: Myriad Genetics (MYGN), down 8% after company denied request for injunction against rival... Vipshop (VIPS), down 4% following downgrade to Neutral rating at Goldman.
News For FCEL;PLUG;BYD;JCP;AEO;ZBB;BONT;LJPC;MYGN;FTEK;VIPS;EJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
11:38 EDTJCPKohl's sinks after profit, sales growth outlook misses expectations
Subscribe for More Information
09:34 EDTBYDNevada reports September statewide gaming win down 5.97% to $901.7M
Subscribe for More Information
October 27, 2014
07:14 EDTMYGNMyriad Genetics announces inclusion of Prolaris test on NCCN Guidelines
Myriad Genetics announced that its Prolaris test has been included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, or NCCN Guidelines, for all men with localized prostate cancer, regardless of their risk category. The NCCN guidelines provide treatment recommendations to ensure that patients receive diagnostic treatment and services that are likely to improve clinical outcomes. Specifically, the updated NCCN guidelines include the use of the Prolaris test to help patients better assess their risk of disease specific mortality and biochemical recurrence. Importantly, Prolaris is supported by seven peer-reviewed publications and is the first and only genetic test for prostate cancer that is: Proven and validated based on gold standard clinical endpoints of disease recurrence and prostate cancer-specific death in untreated men, thus identifying men who can safely forgo initial surgery or radiation and be managed with active surveillance; Proven in clinical utility studies to change treatment recommendations for up to 65% of prostate cancer patients in all risk categories, which may enhance adherence to recommended treatments; and to receive a draft local coverage determination, or LCD, for Medicare reimbursement for low-risk patients.
October 24, 2014
12:21 EDTAEOAbercrombie & Fitch retreats after Goldman cuts to Sell
Subscribe for More Information
10:29 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
10:03 EDTAEOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:05 EDTMYGNMyriad Genetics establishes tumor BRACAnalysis CDx lab in Europe
Myriad Genetics, announced it has established a Tumor BRACAnalysis CDx laboratory in Europe. Myriad's next-generation Tumor BRACAnalysis CDx test is a companion diagnostic that will identify up to 50% more patients with BRAC mutations who may benefit from treatment with PARP inhibitors, such as olaparib, compared to conventional germline testing alone. Olaparib is a novel PARP inhibitor being developed by AstraZeneca. Earlier today, the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, recommended marketing authorization for olaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated, or germline and/or somatic, high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy. It is estimated that more than 22% of all ovarian cancer patients carry a deleterious germline or somatic mutation in the BRCA1 or BRCA2 genes and may benefit from olaparib therapy.
06:40 EDTAEOAmerican Eagle downgraded to Neutral from Buy at Goldman
Subscribe for More Information
October 23, 2014
15:53 EDTLJPCLa Jolla's GCS-100 Phase 2a abstract released, says Jefferies
Subscribe for More Information
October 21, 2014
10:00 EDTAEOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:06 EDTAEOAmerican Eagle initiated with an Outperform at BlueFin
Subscribe for More Information
October 20, 2014
08:22 EDTZBBZBB Energy initiated with a Buy at Craig-Hallum
Subscribe for More Information
October 17, 2014
16:55 EDTJCPStocks end volatile week lower amid oil price plunge
Subscribe for More Information
12:52 EDTMYGNOn The Fly: Midday Wrap
Stocks on Wall Street were sharply higher at midday, as the averages bounce back following steep declines in several recent sessions. Better than expected earnings from General Electric (GE) and Morgan Stanley (MS), a rebound in European stock markets and a stronger than expected reading on U.S. consumer confidence may all be contributing to the brightened mood evidenced by today's trading. ECONOMIC EVENTS: In the U.S., housing starts rebounded 6.3% to a 1.017M pace in September, beating expectations for a monthly increase of 4.6%. Building permits increased 1.5% to a 1.018M rate, which was below the expected 2.3% rise. The first release on the University of Michigan's consumer sentiment index for October came in at 86.4, versus expectations for a decline to 84.0 from the prior 84.6 reading. COMPANY NEWS: General Electric shares rose over 3% after the company reported better than expected third quarter profit and nearly in-line revenues. Morgan Stanley, whose quarterly results also topped Street expectations, advanced 2.5%. MAJOR MOVERS: Among the notable gainers was Westmoreland Coal (WLB), which gained 23% after it stuck a deal to acquire Oxford GP, the general partner of Oxford Resource Partners (OXF), and contribute certain royalty bearing coal reserves to Oxford in return for Oxford common units. Afterward, Brean Capital raised its price target on Westmoreland to $60, noting the announcement represents an entry into the MLP space. Also higher were shares of Textron (TXT), which advanced 11% after the aircraft and defense company reported better than expected third quarter earnings per share and raised its profit outlook for fiscal 2014. Among the noteworthy losers was Urban Outfitters (URBN), which dropped 13% and was downgraded by at least three Street research firms after the owner of Anthropologie and its namesake clothing stores warned that its Q3 earnings may be negatively impacted by continued weakness in its comparable retail sales. Also lower was Myriad Genetics (MYGN), which fell 7% after guiding to lower than expected Q1 adjusted earnings, citing a higher than expected increase in costs to perform its myRisk Hereditary Cancer test following the test's national launch. INDEXES: Near midday, the Dow was up 295.34, or 1.83%, to 16,412.58, the Nasdaq was up 62.43, or 1.48%, to 4,279.82, and the S&P 500 was up 29.48, or 1.58%, to 1,892.24.
10:43 EDTAEOUrban Outfitters slumps after warning on continued retail sales weakness
Subscribe for More Information
07:16 EDTMYGNMyriad Genetics receives draft medicare coverage for Prolaris
Myriad Genetics announced that Palmetto GBA, a Medicare Administrative Contractor, or MAC, that assesses molecular diagnostic technologies, has issued a draft local coverage determination, or LCD, for Prolaris, Myriad's prostate cancer test. The LCD is posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services, or CMS, website and establishes the coverage policy for Medicare beneficiaries. The current language in the draft LCD provides reimbursement coverage for the approximately 50% of prostate cancer patients defined as low and very low risk. Under Medicare rules, the draft LCD is subject to a minimum 45-day public comment period. After comments are considered, a final LCD is issued, which goes into effect after a minimum 45-day notification period.
07:14 EDTMYGNMyriad Genetics sees FY15 EPS $1.90-$2.00, consensus $1.93
Backs FY15 revenue guidance of $800M-$820M, consensus 804.15M.
07:14 EDTMYGNMyriad Genetics sees Q1 adjusted EPS 25c, consensus 41c
Subscribe for More Information
07:00 EDTMYGNMyriad Genetics trading halted, pending news
Subscribe for More Information
05:55 EDTEJE-House upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded E-House to Buy citing the recent pullback in shares and the company's total solution strength. The firm keeps a $14.10 price target for shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use